Contracts › FA460023F0086
FA460023F0086: Medical Countermeasure Drug Discovery & Development Increment 3
Awarded to National Strategic Research Institute by Department of the Air Force.
$10.7Mobligated
$24.5Mpotential value
31 August 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | FA460023F0086 |
|---|---|
| Vehicle | FA460020D0003 |
| Awardee | National Strategic Research Institute |
| Awarding agency | Department of the Air Force |
| Awarding office | FA4600 55 CONS PKP |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AC32 National Defense R&D Services; Defense-Related Activities; Applied Research |
| Place of performance | NE |
| Period of performance | 01 September 2023 to 31 August 2026 |
| Potential end | 31 August 2028 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record